Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A national survey found that primary care physicians had little interest in prescribing buprenorphine or naltrexone.
Even after federal regulators relaxed rules requiring daily clinic visits, these bad actors are still bringing patients in for monitoring.
The coronavirus pandemic has upended the usual systems governing the dispensation of medication-assisted treatment.
Buprenorphine is a treatment for people with opioid use disorder.
Experts are calling for greater flexibility in clinicians’ ability to deliver treatments for opioid use disorder.
One bill would create 1,000 new residency positions for physicians going into addiction treatment medicine.
A systematic review of hep C treatment outcomes in this population shows they have high cure rates and relatively low reinfection rates.
Researchers examined increasing use of PrEP, expanding access to opioid use disorder treatment and improving engagement with HIV care.
Researchers found critical gaps in the scientific knowledge about the opioid epidemic.
The state will provide prisoners medication-assisted treatment to treat opioid use disorder and is creating more syringe services programs.
Researchers followed people with a drug-injection history who had been cured of hepatitis C and were receiving addiction treatment.
Over $12 million in grants has been awarded to the Wistar Institute to research the links between opioid receptors and immune activation.
The first national study of opioid use disorder recovery found that staying off such drugs often requires great effort and various services.
Researchers used mathematical modeling to analyze the benefits of treating with buprenorphine/naloxone on-site.
People living below a highway overpass might be forced into treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.